Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Quarterly Earnings Results, Beats Expectations By $0.23 EPS

Posted by Scott Moore on Nov 9th, 2024

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) released its earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.23, RTT News reports. The business had revenue of $14.97 million during the quarter. During the same period in the prior year, the firm earned ($0.37) EPS.

Barinthus Biotherapeutics Price Performance

NASDAQ BRNS traded down $0.12 during trading hours on Friday, hitting $1.35. The company had a trading volume of 43,853 shares, compared to its average volume of 23,685. Barinthus Biotherapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $4.16. The firm’s 50 day moving average is $1.29 and its 200 day moving average is $1.57. The company has a market capitalization of $53.22 million, a price-to-earnings ratio of -0.91 and a beta of -0.59.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday. Alliance Global Partners dropped their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research note on Tuesday, August 13th.

Read Our Latest Stock Report on Barinthus Biotherapeutics

About Barinthus Biotherapeutics

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.